Absci Corporation (NASDAQ:ABSI) Stock Has Average Target Price of $13.71
Absci Corporation (NASDAQ:ABSI) has received a "Moderate Buy" consensus rating from nine analysts, with an average 12-month target price of $13.71, exceeding its current share price of $11.07. Despite recent weaker-than-expected quarterly results and high volatility, institutional investors hold a significant stake in the company. The stock has shown substantial growth from its one-year low, trading above key moving averages.
Absci (NASDAQ:ABSI) Stock Jumps 6.1% - Still a Buy?
Absci (NASDAQ:ABSI) shares surged 6.1% to $10.0650, despite trading at half its average volume. While analysts maintain a "Moderate Buy" consensus with a $13.71 price target, the company recently missed earnings and revenue estimates, reporting a $0.21 per-share loss. Institutional ownership stands at 52.05%, but the company faces projections of a full-year loss of $0.74 per share.
Guggenheim reiterates Absci stock rating on endometriosis trial delay
Guggenheim has reiterated a Buy rating and a $15.00 price target for Absci Corp. (NASDAQ:ABSI) despite the company announcing a delay in its Phase 2 trial for an endometriosis treatment, pushing the start date to mid-2027. The firm believes the extended timeline for the 150-patient placebo-controlled trial, which will measure dysmenorrhea and non-menstrual pelvic pain, is beneficial to ensure clear data, with results now expected in 2028. Absci's stock has surged 257% over the past year, though InvestingPro data suggests it may be overvalued relative to its Fair Value.
Absci Corporation $ABSI Shares Newly Acquired by Bank of America Corp DE
Bank of America Corp DE has acquired 565,999 shares of Absci Corporation (NASDAQ:ABSI), valued at approximately $6.56 million, representing 0.33% of the company. Other institutional investors have also increased their stakes in Absci, with hedge funds and institutional investors collectively owning 52.05% of the stock. Despite a recent earnings miss, analysts maintain a "Moderate Buy" rating with an average target price of $13.71, significantly higher than its current trading price of $9.74.
Guggenheim reiterates Absci stock rating on endometriosis trial delay By Investing.com
Guggenheim maintained its Buy rating and $15.00 price target for Absci Corp. (NASDAQ:ABSI) despite the company delaying its Phase 2 endometriosis trial (STORYLINE) to mid-2027. The delay is attributed to waiting for more data from an ongoing hair loss trial (HEADLINE) to inform dose selection for STORYLINE. Although Absci's stock has surged 257% over the past year, InvestingPro data suggests it may be overvalued, and the company recently reported a wider-than-expected loss and lower revenue for Q2 2026, though it retains over $200 million in cash.
Guggenheim reiterates Absci stock rating on endometriosis trial delay By Investing.com
Guggenheim maintained a Buy rating and $15.00 price target on Absci Corp. (NASDAQ:ABSI) despite the company delaying its Phase 2 endometriosis trial to mid-2027. The delay is attributed to waiting for more safety and pharmacokinetic data from an ongoing hair loss trial to inform dose selection for the endometriosis study. While the stock has seen a significant surge over the past year, InvestingPro data suggests it may be overvalued.
Absci Stock In Focus As Phase 2 Trial Plan Takes Shape
Absci has detailed the plan for its global Phase 2 STORYLINE trial of ABS-201 for endometriosis, which will be a double-blind, randomized, placebo-controlled study targeting about 150 patients across at least 10 countries. This trial aims to test a differentiated, nonhormonal approach using Absci's generative AI engineered anti-PRLR antibody. The company's investment narrative heavily relies on the success of ABS-201, with minimal current revenue and ongoing losses, projecting significant revenue and earnings growth by 2029 if the trial proves successful.
LifeSci Capital Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16
LifeSci Capital has reiterated its Buy rating on Absci Corp (ABSI.US), maintaining its price target at $16. This indicates a continued positive outlook from the firm regarding Absci Corp's stock performance and future prospects.
Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis
Absci has announced preliminary details for its Phase 2 STORYLINE trial, which will evaluate the AI-designed antibody ABS-201 for the treatment of endometriosis. The trial aims to assess the efficacy and safety of ABS-201, a novel therapeutic developed using artificial intelligence. This marks a significant step in potentially bringing a new treatment option to patients suffering from endometriosis.
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Absci Corporation has announced preliminary details for its Phase 2 STORYLINE™ clinical trial of ABS-201, an AI-designed antibody for endometriosis. The trial will assess the efficacy and safety of ABS-201 in approximately 150 patients with surgically-diagnosed endometriosis and moderate to severe pain, focusing on reductions in dysmenorrhea and non-menstrual pelvic pain. The company anticipates initiating the trial in mid-2027, pending regulatory clearance and protocol finalization, and aims to offer a non-hormonal treatment option for endometriosis-associated pain.
Absci plans phase 2 trial of ABS-201 for endometriosis in 2027
Absci Corporation (NASDAQ:ABSI) announced its intention to initiate a Phase 2 clinical trial, named STORYLINE, for ABS-201, an anti-prolactin receptor antibody, to treat endometriosis-associated pain. The double-blind, randomized, placebo-controlled study is expected to begin in mid-2027 and will assess the efficacy and safety of ABS-201 in approximately 150 patients with surgically-diagnosed endometriosis. This investigational drug, engineered using Absci’s generative AI platform, represents a non-hormonal approach to managing endometriosis.
Absci Plans Phase 2 Endometriosis Trial for Mid-2027 | ABSI Stock News
Absci (ABSI) announced preliminary plans for its Phase 2 STORYLINE™ trial of ABS-201™ for endometriosis, an AI-designed antibody. The global, double-blind, randomized, and placebo-controlled trial is anticipated to start in mid-2027 and will recruit approximately 150 patients across 10 or more countries. The trial will assess the efficacy and safety of ABS-201, focusing on reductions in menstrual and non-menstrual pelvic pain in patients with surgically diagnosed endometriosis.
Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027
Absci (ABSI) announced its intention to start a global, multi-center mid-stage clinical trial for ABS-201, a treatment for endometriosis, in mid-2027. The company expects to initiate this trial to evaluate the drug's efficacy and safety for patients. Access to the full details of this announcement requires a premium subscription.
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Absci Corporation has announced preliminary details for its global, multi-center Phase 2 STORYLINE™ clinical trial of ABS-201™, an AI-designed anti-prolactin receptor antibody, for endometriosis. The trial aims to assess the efficacy and safety of ABS-201™ in patients with surgically diagnosed endometriosis and moderate to severe endometriosis-associated pain, with an anticipated initiation in mid-2027. Absci believes ABS-201™ offers a novel, non-hormonal approach to address the significant unmet medical need in endometriosis treatment.
Absci (NASDAQ:ABSI) Earns "Buy" Rating from Needham & Company LLC
Needham & Company LLC has reaffirmed its "buy" rating on Absci (NASDAQ:ABSI) and set an $11.00 price target, representing a potential upside of 2.71%. This recommendation comes despite Absci reporting a quarterly loss of $0.21 per share and revenue of $0.32 million, both missing analyst estimates. Institutional investors, including BlackRock Inc. with a significant new position, own over 52% of the company's stock.
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
Wall Street analysts predict a 28.3% upside for Absci Corporation (ABSI), with a mean price target of $13.6, despite a recent 55.9% gain. While such price targets can be misleading, a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) suggest potential upside. Investors are cautioned to treat price targets with skepticism and consider deeper fundamental research.
Absci (ABSI) Stock Looks Expensive Against Its Book Value
Absci (ABSI) stock appears expensive when evaluated against its book value, trading at a price-to-book ratio of 6.8x compared to the biotech industry average of 2.2x. This high valuation raises questions about whether the company's pipeline, partnerships, and cash position justify such a premium, especially given that the business is still loss-making. Analysts offer both bullish and bearish perspectives, with some suggesting significant undervaluation while others point to substantial overvaluation based on future growth and partnership prospects.
Absci Corporation (ABSI) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Absci Corporation (ABSI) stock, showing a current price of $9.59 with a 10.50% decrease. It indicates that there are no current analyst ratings or earnings information available for the company. The site also includes various trading guides and disclaimers about the risks and low profitability rates associated with day trading.
Absci at Morgan Stanley healthcare conference: AI platform meets clinical test
Absci presented its AI-led drug discovery model and two lead clinical programs at the Morgan Stanley 24th Annual Global Healthcare Conference. The company highlighted encouraging early safety data for its hair-loss program ABS-201, a large potential market, and a strong cash runway into the second half of 2028. Absci also discussed its endometriosis program and how its AI platform, Atlas, significantly reduces drug discovery timelines and costs.
Squarepoint Ops LLC Sells 228,841 Shares of Absci Corporation $ABSI
Squarepoint Ops LLC significantly reduced its stake in Absci Corporation (NASDAQ:ABSI) by selling 228,841 shares in the second quarter, retaining 162,449 shares. This comes despite Absci reporting weaker-than-expected quarterly results, with institutional investors collectively owning 52.05% of the company. Analysts, however, maintain a "Moderate Buy" consensus rating with an average price target of $13.71, exceeding its current trading price.
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
Shares of hair-loss drug developers like Veradermics (MANE) and Absci (ABSI) are surging as investors look for the "next Ozempic." Veradermics has seen a nearly 500% increase since its IPO, while Absci's stock has more than doubled in 2026, driven by an underserved market and positive clinical results for potential new treatments. However, concerns about clinical uncertainty, out-of-pocket costs, and high competition could limit their growth compared to the GLP-1 drug boom.
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Brokerages
Absci Corporation (NASDAQ:ABSI) has received a consensus rating of "Moderate Buy" from brokerages, with eight out of nine analysts recommending a buy and one a sell. The average 12-month price target is $13.71, while the company recently missed quarterly expectations with a $0.21 loss per share and lower-than-anticipated revenue. Institutional investors hold 52.05% of the stock, with several firms increasing their stakes.
Absci (NASDAQ:ABSI) Price Target Raised to $16.00
BTIG Research has increased its price target for Absci (NASDAQ:ABSI) from $13.00 to $16.00, maintaining a "buy" rating and suggesting an 81.41% potential upside. Despite recent quarterly earnings missing analyst expectations, institutional investors hold over half of the company's stock. Absci, a biotechnology company, leverages machine learning, synthetic biology, and automation to accelerate the discovery and development of protein-based therapeutics.
LifeSci Capital Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $16
LifeSci Capital has initiated coverage on Absci Corp (ABSI.US) with a "Buy" rating. The firm has set a target price of $16 for the stock. This new rating and price target indicate a positive outlook from LifeSci Capital for Absci Corp.
Bank of New York Mellon Corp Buys Shares of 386,832 Absci Corporation $ABSI
Bank of New York Mellon Corp acquired a new position in Absci Corporation, purchasing 386,832 shares valued at approximately $4.48 million, representing about 0.25% of the company. Institutional investors collectively own 52.05% of Absci, which recently reported a quarterly loss and revenue miss. Despite this, analysts maintain a "Moderate Buy" consensus with an average price target significantly higher than the current stock price.
Absci Corporation $ABSI Shares Bought by Bank of America Corp DE
Bank of America Corp DE significantly increased its stake in Absci Corporation (NASDAQ:ABSI) by 55.2% in the first quarter, now holding 487,193 shares valued at approximately $1.46 million. This move is part of a broader trend of institutional investors, who collectively own 52.05% of the company, adjusting their positions. Despite missing quarterly earnings expectations with a loss of $0.21 per share and revenue of $0.32 million, Absci maintains a "Moderate Buy" consensus rating from analysts with an average price target of $13.43.
Absci Corp CFO Zachariah Jonasson Reports RSU Tax Withholding Share Transaction
Absci Corp's CFO and CBO, Zachariah Jonasson, reported a share withholding transaction related to the vesting of restricted stock units (RSUs). On August 31, 2026, 8,320 common stock shares were withheld at $8.71 per share by the issuer to cover tax withholding requirements. This was not a discretionary sale, and following the transaction, Jonasson directly owns 483,144 common stock shares in the company.
Absci (NASDAQ:ABSI) Stock Price Down 4.8% - Should You Sell?
Absci (NASDAQ:ABSI) stock fell by 4.8% on Wednesday to $8.4160, with trading volume significantly lower than average. Despite missing quarterly earnings and revenue estimates, analysts maintain a "Moderate Buy" consensus rating with an average price target of $13.43. Institutional investors own over half of the company's stock, and Absci leverages machine learning and synthetic biology for drug discovery.
Absci to Participate in Upcoming Investor Conferences
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company utilizing generative AI for therapeutics, announced its participation in two upcoming investor conferences. The company will hold fireside chats at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16th. These events will allow Absci to discuss its Integrated Drug Creation™ platform and its pipeline, including ABS-201™ for hair regrowth and endometriosis.
Absci to Participate in Upcoming Investor Conferences
Absci Corporation, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences: the H.C. Wainwright 28th Annual Global Investment Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The company will hold fireside chats at both events in mid-September 2026, which will be accessible via live and archived webcasts on its investor relations website. Absci is focused on advancing drug discovery with generative AI and has a pipeline of AI-designed therapeutics, including ABS-201 for hair regrowth and endometriosis.
BlackRock Inc. Buys Shares of 12,175,302 Absci Corporation $ABSI
BlackRock Inc. recently acquired 12.18 million shares of Absci Corporation (NASDAQ:ABSI) valued at approximately $141.1 million, giving it a 7.81% stake in the biotechnology company. This investment comes despite Absci reporting weaker-than-expected quarterly results, missing revenue and EPS consensus estimates. Analysts, however, maintain a generally positive outlook on the stock, with a consensus "Moderate Buy" rating and a target price significantly higher than its current trading price.
Deutsche Bank AG Acquires New Stake in Absci Corporation $ABSI
Deutsche Bank AG has acquired a new stake in Absci Corporation (NASDAQ:ABSI) during the second quarter of 2026, purchasing 137,265 shares valued at approximately $1.59 million. This acquisition gives Deutsche Bank a 0.09% ownership in Absci, while institutional investors and hedge funds collectively hold 52.05% of the company's stock. Despite a recent 7.5% drop in stock price and a wider-than-expected quarterly loss, analysts maintain a "Moderate Buy" consensus with an average price target of $13.43 for Absci.
Artia Global Partners LP Acquires Shares of 464,444 Absci Corporation $ABSI
Artia Global Partners LP has acquired 464,444 shares of Absci Corporation (NASDAQ:ABSI) valued at approximately $5.38 million, representing about 0.27% of the company. Institutional investors collectively own 52.05% of Absci, and analysts generally have a "Moderate Buy" rating with an average target price of $13.43. Despite the institutional interest, Absci recently reported weaker-than-expected quarterly results, missing revenue and EPS estimates.
Absci (NASDAQ:ABSI) Trading 8.5% Higher - What's Next?
Absci (NASDAQ:ABSI) saw its shares trade 8.5% higher during mid-day trading, despite volume being significantly lower than its daily average. The company faces mixed analyst sentiment with a "Moderate Buy" consensus but had weaker-than-expected quarterly results, missing both EPS and revenue estimates. Institutional investors, including BlackRock Inc. and State Street Corp, have recently increased their positions in the AI biotech company.
Parkman Healthcare Partners LLC Acquires New Shares in Absci Corporation $ABSI
Parkman Healthcare Partners LLC has acquired 894,374 new shares in Absci Corporation (NASDAQ:ABSI) valued at approximately $10.4 million, establishing a 0.52% stake. This move comes as institutional investors and hedge funds collectively own over half of the company's stock. Despite a recent quarterly loss and missed revenue estimates, analysts maintain a "Moderate Buy" consensus for Absci with an average price target of $13.43.
Absci (NASDAQ:ABSI) Shares Down 7.8% - Should You Sell?
Absci (NASDAQ:ABSI) shares dropped 7.8% on Monday, trading down to $8.80 with significantly lower than average volume. Despite the recent decline and a miss on Q2 earnings expectations, analyst sentiment remains a "Moderate Buy" with a consensus price target of $13.43. The company, which focuses on AI-driven protein therapeutic discovery, has a high beta and a market capitalization of $1.52 billion.
Certain Common Stock of Absci Corporation are subject to a Lock-Up Agreement Ending on 24-AUG-2026.
This article announces that certain common stock of Absci Corporation is under a lock-up agreement set to expire on August 24, 2026. The lock-up period, which began on June 24, 2026, restricts officers and directors from selling, pledging, or transferring common stock or convertible securities for 60 days. This measure aims to prevent the immediate disposition of shares following a prospectus date, maintaining market stability.
Certain Stock Options of Absci Corporation are subject to a Lock-Up Agreement Ending on 24-AUG-2026.
Certain stock options of Absci Corporation are under a 60-day lock-up agreement, preventing officers and directors from selling or transferring them. This restriction began on June 24, 2026, and concludes on August 24, 2026, aiming to prevent economic consequences of ownership transfer during this period. The agreement applies to all common stock and convertible securities.
How Positive ABS-201 Phase 1 Data And Pipeline Momentum At Absci (ABSI) Has Changed Its Investment Story
Absci Corporation (ABSI) reported positive interim Phase 1 data for ABS-201, a treatment for pattern hair loss, showing a favorable safety profile and a long half-life, with plans to expand its use to endometriosis and advance to Phase 2 in 2026. This data de-risks ABS-201's tolerability and dosing, supporting the company's investment narrative, which relies heavily on the success of this AI-designed antibody despite current losses and a concentrated pipeline. Investors will be watching for the 2026 proof-of-concept readout, which is crucial for the company's future valuation and stock performance.
Morgan Stanley Maintains Absci Corp(ABSI.US) With Hold Rating, Raises Target Price to $10
Morgan Stanley has reiterated its "Hold" rating for Absci Corp (ABSI.US) and increased the stock's target price to $10. This indicates a maintained neutral stance while acknowledging potential for a higher valuation.
Absci (NASDAQ:ABSI) Shares Gap Up - Should You Buy?
Absci (NASDAQ:ABSI) shares gapped up, opening at $9.42 after closing at $8.85, and later traded near $9.64. The company, which applies AI and synthetic biology for protein-based therapeutics, has a "Moderate Buy" consensus from analysts with an average price target of $13.43, despite missing recent earnings estimates and remaining unprofitable. Institutional investors hold over 52% of the shares, showing significant interest in the company.
Absci (ABSI) Q2 2026 Earnings Call Transcript
Absci (ABSI) reported its Q2 2026 financial results, highlighting a net loss of $33.2 million and revenue of $0.3 million, reflecting fluctuations in partner program milestones. The company secured $93.6 million in financing proceeds, including a $40 million strategic investment from Eli Lilly, extending its cash runway into the second half of 2028. Absci emphasized the advancement of its ABS-201 program for pattern hair loss and endometriosis, driven by its AI-powered Atlas discovery engine, and anticipates key clinical data readouts in late 2026 and early 2027.
Morgan Stanley Maintains Absci Corp(ABSI.US) With Hold Rating, Raises Target Price to $10
Morgan Stanley has reiterated its "Hold" rating for Absci Corp (ABSI.US) and has increased its target price for the stock to $10. This indicates a continued neutral stance on the company's stock while acknowledging a potentially improved outlook.
ABSI Looks 1092.2% Overvalued on GF Value™
Absci Corp (NASDAQ: ABSI) reported Q2 revenue significantly below analyst expectations, yet its CEO highlighted promising interim results from its HEADLINE trial. Despite a GF Score of 46/100, indicating mixed fundamentals and challenges in profitability, insider activity shows net buying. The company's Price-to-Sales ratio of 918x is extremely high, and the GF Value™ estimates it as 1092.2% overvalued, suggesting high investor expectations for future growth amidst current losses.
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts
Absci Corporation (NASDAQ:ABSI) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $13.43. Despite missing quarterly earnings and revenue estimates, institutional investors hold over 52% of the stock. The company leverages machine learning and synthetic biology in its Integrated Drug Creation® platform for developing protein-based therapeutics.
Will Absci (NASDAQ:ABSI) Spend Its Cash Wisely?
This article analyzes Absci's financial health, specifically its cash burn rate and cash reserves, to assess its ability to fund operations and future growth. It examines the company's current cash runway, which is estimated to be over two years based on recent expenditures. The analysis suggests that while Absci has a substantial cash position, it will need to manage its spending effectively to avoid needing to raise additional capital in the near future.
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $11
Needham has reiterated its Buy rating for Absci Corp (ABSI.US), maintaining a price target of $11. This indicates the firm's continued positive outlook on the company's stock performance.
Why Absci (ABSI) Is Up 14.0% After Positive Early ABS-201 Hair Loss Data And Endometriosis Plans
Absci Corporation's stock (ABSI) rose 14.0% after reporting positive interim Phase 1 results for ABS-201, a drug targeting pattern hair loss, showing favorable safety and tolerability. The company also announced plans to advance ABS-201 to Phase 2 testing for endometriosis in late 2026. This dual focus and long-acting profile could significantly expand Absci's market opportunities, though the company continues to face financial strain with substantial net losses.
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright has reiterated its Buy rating for Absci Corp (ABSI.US) and maintained a target price of $16. This indicates continued confidence from the firm in the company's stock performance.
Absci Corp. Earnings Call Highlights ABS-201 And Cash
Absci Corp.'s Q2 earnings call highlighted promising interim Phase I data for its flagship antibody ABS-201, showing favorable safety, tolerability, and a long half-life. The company's financial position has been significantly strengthened by a recent $100 million financing, including a $40 million strategic investment from Eli Lilly, providing a cash runway into 2028. Absci outlined clear clinical milestones for ABS-201 in pattern hair loss and endometriosis, targeting multi-billion dollar markets while acknowledging that efficacy and durability still need to be fully proven in future unblinded data readouts.
